ICU Medical Reports Reduced Q4 Net Loss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Should l Buy ICUI?
Source: NASDAQ.COM
- Q4 Financial Performance: ICU Medical reported a net loss of $15.7 million for Q4 2026, translating to a loss of $0.64 per share, which is an improvement from a net loss of $23.8 million or $0.97 per share in Q4 2024, indicating efforts in cost control.
- Adjusted EPS Decline: The adjusted earnings per share for Q4 were $1.91, down from $2.11 in 2024, reflecting challenges in revenue and profitability that may impact investor confidence moving forward.
- Revenue Decline: Q4 revenue stood at $540.7 million, a decrease from $629.8 million in the same period last year, suggesting weak market demand and the need for strategic measures to regain growth momentum.
- Future Outlook: The company projects net income for fiscal year 2026 to range between $26 million and $44 million, with earnings per share estimated between $1.03 and $1.74, reflecting a cautiously optimistic outlook from management regarding future profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICUI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICUI
Wall Street analysts forecast ICUI stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 149.740
Low
172.00
Averages
173.50
High
175.00
Current: 149.740
Low
172.00
Averages
173.50
High
175.00
About ICUI
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ICU Medical Reports Revenue Decline in 2025 Financials
- Revenue Decline: ICU Medical reported a nearly 14% year-over-year decline in total revenue for Q4 2025, dropping to $540.40 million from $629.81 million, indicating weakened market demand and increased competition.
- Narrowed Net Loss: The company's net loss for Q4 narrowed to $15.73 million, or $0.64 per share, yet adjusted net income fell to $48.12 million, or $1.91 per share, reflecting ongoing pressure on profitability despite improvements.
- Annual Performance Improvement: For the full year 2025, ICU Medical reported a net income of $0.73 million, or $0.03 per share, a significant turnaround from a net loss of $117.69 million, showcasing effective cost control and business restructuring efforts.
- Future Outlook: Looking ahead, ICU Medical expects net income for 2026 to range between $26 million and $44 million, with adjusted EBITDA projected at $400 million to $430 million, demonstrating confidence in future growth despite ongoing market challenges.
See More
ICU Medical Reports Q4 2025 Earnings Highlights
- Revenue Growth: ICU Medical reported Q4 2025 revenue of $536 million, reflecting a 14% decline in reported terms but achieving 2% organic growth, with a full-year organic growth of 5%, indicating the company's stability and growth potential in the market.
- Cost and Profit Analysis: The adjusted gross margin stood at 40.5%, aligning with prior guidance, while adjusted EBITDA was $98 million, a 7% decrease year-over-year primarily due to the deconsolidation of IV Solutions and tariffs, highlighting challenges in cost control.
- Future Outlook: The company anticipates organic revenue growth in the low to mid-single-digit range for 2026, with an adjusted EBITDA target of $400 million to $430 million, reflecting management's confidence in future growth and market demand.
- Strategic Integration Progress: Management emphasized the completion of several integration milestones, including the closure of the FDA warning letter, which is expected to provide more strategic options for the company and further drive innovation and operational synergies.
See More
ICU Medical Reports Reduced Q4 Net Loss
- Q4 Financial Performance: ICU Medical reported a net loss of $15.7 million for Q4 2026, translating to a loss of $0.64 per share, which is an improvement from a net loss of $23.8 million or $0.97 per share in Q4 2024, indicating efforts in cost control.
- Adjusted EPS Decline: The adjusted earnings per share for Q4 were $1.91, down from $2.11 in 2024, reflecting challenges in revenue and profitability that may impact investor confidence moving forward.
- Revenue Decline: Q4 revenue stood at $540.7 million, a decrease from $629.8 million in the same period last year, suggesting weak market demand and the need for strategic measures to regain growth momentum.
- Future Outlook: The company projects net income for fiscal year 2026 to range between $26 million and $44 million, with earnings per share estimated between $1.03 and $1.74, reflecting a cautiously optimistic outlook from management regarding future profitability.
See More
ICU Medical Reports Q4 Earnings Beat Expectations
- Earnings Beat: ICU Medical reported a Q4 non-GAAP EPS of $1.91, exceeding expectations by $0.22, indicating strong profitability despite revenue challenges.
- Revenue Decline: The company recorded Q4 revenue of $540.7 million, a 14.1% year-over-year decline, yet this figure aligns with market expectations, showcasing stability in a challenging environment.
- Fiscal Year 2026 Guidance: ICU Medical estimates GAAP net income for FY 2026 to range between $26 million and $44 million, with GAAP EPS projected between $1.03 and $1.74, reflecting cautious optimism about future profitability.
- Adjusted EBITDA Outlook: The company anticipates adjusted EBITDA for FY 2026 to be between $400 million and $430 million, with adjusted EPS expected to range from $7.75 to $8.45, demonstrating confidence in strategic growth plans moving forward.
See More
ICU Medical Set to Release Q4 Earnings on February 19
- Earnings Announcement Schedule: ICU Medical is set to announce its Q4 earnings on February 19 after market close, with consensus EPS estimate at $1.69, reflecting a 19.9% year-over-year decline, and revenue estimate at $541.2 million, down 14.1% year-over-year, indicating challenges ahead for the company.
- Historical Performance: Over the past two years, ICU Medical has consistently beaten EPS and revenue estimates 100% of the time, showcasing the company's reliability in financial forecasting and bolstering investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision with no downward adjustments, while revenue estimates experienced one downward revision without any upward changes, reflecting a cautious market outlook on the company's future performance.
- Industry Conference Participation: ICU Medical presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the healthcare sector and potentially laying the groundwork for future investor relations activities.
See More
ICU Medical Announces Q4 2025 Earnings Release Schedule
- Earnings Release Schedule: ICU Medical will release its Q4 2025 earnings on February 19, 2026, at 4:00 p.m. ET, reflecting the company's ongoing innovation and development in the medical products sector.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 4:30 p.m. ET on the same day, providing an in-depth analysis of financial results aimed at enhancing investor understanding and confidence in the company's performance.
- Webcast Availability: The conference call will be simultaneously available via webcast, accessible through the company's website, ensuring transparency and availability of information, thereby enhancing interaction with investors.
- Company Background: ICU Medical is a global leader in infusion systems and high-value critical care products, committed to providing quality, innovation, and value to clinical customers worldwide, showcasing the company's leadership position in the healthcare industry.
See More
ICU Medical Reports Revenue Decline in 2025 Financials
- Revenue Decline: ICU Medical reported a nearly 14% year-over-year decline in total revenue for Q4 2025, dropping to $540.40 million from $629.81 million, indicating weakened market demand and increased competition.
- Narrowed Net Loss: The company's net loss for Q4 narrowed to $15.73 million, or $0.64 per share, yet adjusted net income fell to $48.12 million, or $1.91 per share, reflecting ongoing pressure on profitability despite improvements.
- Annual Performance Improvement: For the full year 2025, ICU Medical reported a net income of $0.73 million, or $0.03 per share, a significant turnaround from a net loss of $117.69 million, showcasing effective cost control and business restructuring efforts.
- Future Outlook: Looking ahead, ICU Medical expects net income for 2026 to range between $26 million and $44 million, with adjusted EBITDA projected at $400 million to $430 million, demonstrating confidence in future growth despite ongoing market challenges.
See More
ICU Medical Reports Q4 2025 Earnings Highlights
- Revenue Growth: ICU Medical reported Q4 2025 revenue of $536 million, reflecting a 14% decline in reported terms but achieving 2% organic growth, with a full-year organic growth of 5%, indicating the company's stability and growth potential in the market.
- Cost and Profit Analysis: The adjusted gross margin stood at 40.5%, aligning with prior guidance, while adjusted EBITDA was $98 million, a 7% decrease year-over-year primarily due to the deconsolidation of IV Solutions and tariffs, highlighting challenges in cost control.
- Future Outlook: The company anticipates organic revenue growth in the low to mid-single-digit range for 2026, with an adjusted EBITDA target of $400 million to $430 million, reflecting management's confidence in future growth and market demand.
- Strategic Integration Progress: Management emphasized the completion of several integration milestones, including the closure of the FDA warning letter, which is expected to provide more strategic options for the company and further drive innovation and operational synergies.
See More
ICU Medical Reports Reduced Q4 Net Loss
- Q4 Financial Performance: ICU Medical reported a net loss of $15.7 million for Q4 2026, translating to a loss of $0.64 per share, which is an improvement from a net loss of $23.8 million or $0.97 per share in Q4 2024, indicating efforts in cost control.
- Adjusted EPS Decline: The adjusted earnings per share for Q4 were $1.91, down from $2.11 in 2024, reflecting challenges in revenue and profitability that may impact investor confidence moving forward.
- Revenue Decline: Q4 revenue stood at $540.7 million, a decrease from $629.8 million in the same period last year, suggesting weak market demand and the need for strategic measures to regain growth momentum.
- Future Outlook: The company projects net income for fiscal year 2026 to range between $26 million and $44 million, with earnings per share estimated between $1.03 and $1.74, reflecting a cautiously optimistic outlook from management regarding future profitability.
See More
ICU Medical Reports Q4 Earnings Beat Expectations
- Earnings Beat: ICU Medical reported a Q4 non-GAAP EPS of $1.91, exceeding expectations by $0.22, indicating strong profitability despite revenue challenges.
- Revenue Decline: The company recorded Q4 revenue of $540.7 million, a 14.1% year-over-year decline, yet this figure aligns with market expectations, showcasing stability in a challenging environment.
- Fiscal Year 2026 Guidance: ICU Medical estimates GAAP net income for FY 2026 to range between $26 million and $44 million, with GAAP EPS projected between $1.03 and $1.74, reflecting cautious optimism about future profitability.
- Adjusted EBITDA Outlook: The company anticipates adjusted EBITDA for FY 2026 to be between $400 million and $430 million, with adjusted EPS expected to range from $7.75 to $8.45, demonstrating confidence in strategic growth plans moving forward.
See More
ICU Medical Set to Release Q4 Earnings on February 19
- Earnings Announcement Schedule: ICU Medical is set to announce its Q4 earnings on February 19 after market close, with consensus EPS estimate at $1.69, reflecting a 19.9% year-over-year decline, and revenue estimate at $541.2 million, down 14.1% year-over-year, indicating challenges ahead for the company.
- Historical Performance: Over the past two years, ICU Medical has consistently beaten EPS and revenue estimates 100% of the time, showcasing the company's reliability in financial forecasting and bolstering investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision with no downward adjustments, while revenue estimates experienced one downward revision without any upward changes, reflecting a cautious market outlook on the company's future performance.
- Industry Conference Participation: ICU Medical presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the healthcare sector and potentially laying the groundwork for future investor relations activities.
See More
ICU Medical Announces Q4 2025 Earnings Release Schedule
- Earnings Release Schedule: ICU Medical will release its Q4 2025 earnings on February 19, 2026, at 4:00 p.m. ET, reflecting the company's ongoing innovation and development in the medical products sector.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 4:30 p.m. ET on the same day, providing an in-depth analysis of financial results aimed at enhancing investor understanding and confidence in the company's performance.
- Webcast Availability: The conference call will be simultaneously available via webcast, accessible through the company's website, ensuring transparency and availability of information, thereby enhancing interaction with investors.
- Company Background: ICU Medical is a global leader in infusion systems and high-value critical care products, committed to providing quality, innovation, and value to clinical customers worldwide, showcasing the company's leadership position in the healthcare industry.
See More
